The proprietor of a medical manufacturing company in Ottawa is facing challenges adhering to Canada’s nuclear regulations due to financial constraints. Best Theratronics, known for producing cancer treatment devices using Cobalt-60 radioactive isotopes, received two orders from the Canadian Nuclear Safety Commission (CNSC) in November 2024. One order pertained to safety issues at the plant during a labor dispute with striking workers, while the other mandated a $1.8 million financial guarantee for potential decommissioning costs.
Krishnan Suthanthiran, the company owner, expressed inability to fulfill the financial obligation, citing lack of funds and the unsuitability of the imposed guarantee. He emphasized the difficulty in obtaining a loan from banks to cover the required amount. Suthanthiran criticized the CNSC, alleging non-compliance with its own regulations.
Despite the ongoing violations, the CNSC has not disclosed its course of action for ensuring compliance by Best Theratronics. The commission has the authority to issue fines, revoke licenses, and initiate legal proceedings against licensees. Green Party Leader Elizabeth May criticized Suthanthiran’s conduct, accusing the CNSC of being too lenient and industry-aligned.
Formerly a division of Atomic Energy of Canada and subsequently acquired by Suthanthiran in 2008, Best Theratronics has a historical legacy in cobalt-based cancer therapy systems. Suthanthiran, a Carleton University alumnus and entrepreneur with a global medical manufacturing presence, indicated plans to cease nuclear-licensed operations in Canada due to business challenges. Staffing difficulties arose post-strike, with a significant workforce reduction and recruitment struggles reported by Suthanthiran.
In response to the evolving situation, Suthanthiran proposed continuing some operations at the Kanata plant without a nuclear license. Despite the setbacks and controversies, the company aims to navigate the regulatory landscape and sustain its operations in the changing business environment.